DCM
NRIX icon

DAFNA Capital Management’s Nurix Therapeutics NRIX Stock Holding History

DAFNA Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-556,695
Closed -$4.38M – 79
2023
Q3 		$4.38M Hold
556,695
– – 1.36% 24
2023
Q2 		$5.56M Sell
556,695
-10,000
-2% -$102K 1.52% 21
2023
Q1 		$5.03M Hold
566,695
– – 1.51% 22
2022
Q4 		$6.22M Hold
566,695
– – 1.75% 17
2022
Q3 		$7.38M Hold
566,695
– – 1.99% 16
2022
Q2 		$7.18M Buy
566,695
+23,351
+4% +$265K 1.96% 14
2022
Q1 		$7.61M Buy
543,344
+237,024
+77% +$4.21M 1.98% 13
2021
Q4 		$8.87M Hold
306,320
– – 2.23% 10
2021
Q3 		$9.18M Hold
306,320
– – 2.43% 9
2021
Q2 		$8.13M Hold
306,320
– – 1.7% 13
2021
Q1 		$9.52M Buy
+306,320
New +$11.6M 2.26% 7

Other funds holding NRIX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

DAFNA Capital Management's NRIX Position: Q4 2023 in Review

DAFNA Capital Management sold out of Nurix Therapeutics (NRIX) in Q4 2023, closing a stake of 556,695 shares — an estimated $4.38M sold.

DAFNA Capital Management first reported a position in NRIX in Q1 2021 and held it in 11 quarters. The position peaked at $9.52M in Q1 2021. 130 funds tracked by Wall St. Rank hold NRIX as of Q4 2023.

  • DAFNA Capital Management reported no remaining Nurix Therapeutics position as of Q4 2023 after selling out during the quarter.
  • DAFNA Capital Management sold 556,695 Nurix Therapeutics shares in Q4 2023, an estimated $4.38M.
  • DAFNA Capital Management first reported a position in Nurix Therapeutics in Q1 2021 and held it in 11 quarters.
  • DAFNA Capital Management's Nurix Therapeutics position peaked at $9.52M in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2023.

Based on DAFNA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.